Recent Company News

• 10:11 AM ET Jun 11, 2026
  

  FTC grants antitrust clearance for Otsuka's purchase of Transcend Therapeutics (¥10220.0000, 0)

• 04:22 PM ET Jun 04, 2026
  

  Otsuka presents new eFGR data at ERA Congress; begins rolling submission of sBLA for VOYXACT (14:32ET) (¥10775.0000, 0)

• 07:10 PM ET May 28, 2026
  

  Otsuka Holdings presents new phase 3 post Hoc analyses of centanafadine at ASCP annual meeting

• 10:51 PM ET May 21, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (81 total)

• 11:19 PM ET May 20, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (101 total)

• 10:43 PM ET May 20, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (85 total)

• 11:18 PM ET May 19, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (163 total)

• 11:13 PM ET May 19, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (95 total)

• 02:16 PM ET May 13, 2026
  

  FDA approves sNDA for INQOVI combo for AML in adults 75+ years of age (¥11145.0000, 0)

• 10:47 AM ET May 07, 2026
  

  CORRECTION: MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema (HAE) in patients 12 years and older ($75.76, -1.10)